new
data
highlights
beyondspring
plinabulin
highly
effective
agent
preventing
neutropenia
potential
reduce
clinical
resources
new
york
globe
newswire
beyondspring
inc
company
beyondspring
nasdaq
bysi
global
biopharmaceutical
company
focused
developing
innovative
therapies
transform
lives
patients
unmet
medical
needs
today
announced
new
clinical
data
company
asset
plinabulin
showing
drug
candidate
favorable
option
preventing
neutropenia
cin
pandemic
compared
pegfilgrastim
peg
currently
predominant
therapy
cin
prevention
douglas
blayney
global
principal
investigator
beyondspring
plinabulin
cin
studies
professor
medicine
stanford
medical
school
presented
data
poster
year
esmo
virtual
congress
august
national
comprehensive
cancer
network
nccn
updated
treatment
guidelines
cin
prophylaxis
due
pandemic
aim
preserve
hospital
healthcare
resources
patients
without
compromising
best
care
possible
cancer
patients
patients
receiving
chemotherapy
typically
develop
neutropenia
severe
side
effect
increases
risk
infection
fever
also
called
febrile
neutropenia
fn
necessitates
er
hospital
visits
updated
nccn
guidelines
expand
use
prophylactic
peg
lower
fn
risk
patients
avoid
hospital
er
visits
pandemic
beyondspring
presentation
compares
cin
study
data
plinabulin
alone
mg
peg
alone
mg
two
different
phase
cin
studies
beyondspring
study
study
four
cycles
plinabulin
given
day
chemotherapy
whereas
peg
given
day
chemotherapy
phase
study
cell
lung
cancer
patients
given
docetaxel
chemotherapy
phase
study
breast
cancer
patients
given
tac
taxotere
doxorubicin
cyclophosphamide
chemotherapy
terms
grade
neutropenia
clinical
outcomes
severe
neutropenia
hospitalizations
infections
sepsis
plinabulin
single
agent
equally
effective
peg
importantly
came
thrombocytopenia
bone
pain
plinabulin
demonstrated
advantages
peg
unique
mechanism
action
plinabulin
various
differentiated
benefits
versus
standard
care
peg
said
ramon
mohanlal
beyondspring
chief
medical
officer
executive
vice
president
research
development
first
plinabulin
given
day
chemotherapy
peg
given
hours
chemotherapy
patients
administered
plinabulin
also
experienced
reduced
bone
pain
improved
platelet
counts
compared
peg
time
plinabulin
equally
protected
occurrence
cin
clinical
consequences
especially
important
era
beyondspring
initiated
expanded
access
program
eap
enable
doctors
across
use
plinabulin
prevent
cancer
patients
cin
alone
combination
physician
would
like
request
plinabulin
eap
access
patient
please
email
expandedaccess
information
beyondspring
plinabulin
eap
please
visit
eap
supplies
may
limited
beyondspring
headquartered
new
york
beyondspring
global
biopharmaceutical
company
focused
developing
innovative
cancer
therapies
improve
clinical
outcomes
patients
high
unmet
medical
needs
beyondspring
lead
immune
asset
plinabulin
potent
cell
apc
inducer
currently
two
phase
clinical
trials
two
severely
unmet
medical
needs
indications
one
prevention
neutropenia
cin
frequent
cause
chemotherapy
regimen
dose
decrease
delay
downgrade
discontinuation
lead
suboptimal
clinical
outcomes
cell
lung
cancer
nsclc
treatment
egfr
patients
pipeline
drug
plinabulin
various
combination
studies
boost
antibody
effects
addition
plinabulin
beyondspring
extensive
pipeline
includes
three
assets
drug
discovery
platform
dubbed
molecular
glue
uses
protein
degradation
pathway
plinabulin
plinabulin
beyondspring
lead
asset
differentiated
immune
stem
cell
modulator
plinabulin
currently
clinical
development
increase
overall
survival
cancer
patients
well
alleviate
neutropenia
cin
durable
anticancer
benefits
plinabulin
associated
effect
potent
cell
apc
inducer
dendritic
cell
maturation
activation
chem
cell
reports
plinabulin
cin
data
highlights
ability
boost
number
hematopoietic
stem
progenitor
cells
hspcs
lsk
cells
mice
effects
hspcs
could
explain
ability
plinabulin
treat
cin
also
reduce
thrombocytopenia
increase
circulating
cells
patients
cautionary
note
regarding
statements
press
release
includes
statements
historical
facts
words
expect
anticipate
plan
believe
design
may
future
estimate
predict
objective
goal
variations
thereof
variations
words
similar
expressions
intended
identify
statements
statements
based
beyondspring
current
knowledge
present
beliefs
expectations
regarding
possible
future
events
subject
risks
uncertainties
assumptions
actual
results
timing
events
could
differ
materially
anticipated
statements
result
several
factors
including
limited
difficulties
raising
anticipated
amount
needed
finance
company
future
operations
terms
acceptable
company
unexpected
results
clinical
trials
delays
denial
regulatory
approval
process
results
meet
expectations
regarding
potential
safety
ultimate
efficacy
clinical
utility
product
candidates
increased
competition
market
risks
described
beyondspring
recent
form
file
securities
exchange
commission
statements
made
herein
speak
date
release
beyondspring
undertakes
obligation
update
publicly
statements
reflect
subsequent
events
circumstances
except
otherwise
required
law
